FIELD: biotechnology.
SUBSTANCE: invention relates to an isolated antibody molecule capable of binding to human CD39 (hCD39), as well as to a method for its production. Also an isolated nucleic acid encoding the above antibody is disclosed, as well as a vector and a cell containing it are disclosed. The invention also relates to a method for inducing or enhancing an immune response in a subject, using the above antibody molecule.
EFFECT: invention is effective for treatment of cancer, chronic infection, as well as inflammatory disease.
19 cl, 22 dwg, 2 tbl, 21 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-IGE ANTIBODIES | 2017 |
|
RU2816207C2 |
| ANTIBODIES AGAINST HLA-G, COMPOSITIONS CONTAINING ANTIBODIES AGAINST HLA-G, AND METHODS OF USE OF ANTIBODIES AGAINST HLA-G | 2019 |
|
RU2810326C2 |
| ANTI-αvβ8 ANTIBODIES AND COMPOSITIONS AND THEIR USE | 2019 |
|
RU2812478C2 |
| ANTI-TIGIT ANTIBODIES AND METHODS OF USING | 2016 |
|
RU2732591C2 |
| ANTI-TIGIT ANTIBODIES AND METHODS OF USE | 2016 |
|
RU2817838C2 |
| ANTI-IL-22R-ANTIBODIES | 2017 |
|
RU2758721C2 |
| ANTI-LILRB1 ANTIBODY AND ITS USE | 2020 |
|
RU2801535C1 |
| ANTI-OX40 ANTIBODIES AND THEIR APPLICATION | 2017 |
|
RU2753493C2 |
| ANTI-MET ANTIBODIES AND THEIR USE | 2017 |
|
RU2765267C2 |
| HIGH-AFFINITY ANTI-PD-1 AND ANTI-LAG-3 ANTIBODIES AND BISPECIFIC BINDING PROTEINS OBTAINED FROM THEM | 2019 |
|
RU2782381C2 |
